|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
2004-7-8
|
|
pubmed:abstractText |
Androgen ablation-refractory prostate cancer patients (stage D3) develop painful bone metastases and limited responsiveness to conventional therapies, hence the lack of universally accepted "gold standard" treatment for this poor prognosis clinical setting. We tested the safety and efficacy in stage D3 patients of the combination hormonal therapy, which combines administration of somatostatin analog and dexamethasone with standard androgen ablation monotherapy (luteinizing-hormone releasing-hormone analog or orchiectomy).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4398-405
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15240528-Aged,
pubmed-meshheading:15240528-Aged, 80 and over,
pubmed-meshheading:15240528-Androgens,
pubmed-meshheading:15240528-Antineoplastic Agents, Hormonal,
pubmed-meshheading:15240528-Bone Neoplasms,
pubmed-meshheading:15240528-Dexamethasone,
pubmed-meshheading:15240528-Disease Progression,
pubmed-meshheading:15240528-Disease-Free Survival,
pubmed-meshheading:15240528-Dose-Response Relationship, Drug,
pubmed-meshheading:15240528-Gonadotropin-Releasing Hormone,
pubmed-meshheading:15240528-Hormones,
pubmed-meshheading:15240528-Humans,
pubmed-meshheading:15240528-Male,
pubmed-meshheading:15240528-Middle Aged,
pubmed-meshheading:15240528-Neoplasm Metastasis,
pubmed-meshheading:15240528-Prostate-Specific Antigen,
pubmed-meshheading:15240528-Prostatic Neoplasms,
pubmed-meshheading:15240528-Radionuclide Imaging,
pubmed-meshheading:15240528-Somatostatin,
pubmed-meshheading:15240528-Time Factors,
pubmed-meshheading:15240528-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
|
|
pubmed:affiliation |
Department of Experimental Physiology, Medical School, University of Athens, Goudi-Athens, Greece. mitsiades@dfci.harvard.edu
|
|
pubmed:publicationType |
Journal Article
|
